Loading stock data…
FATE
$2.18-0.21 (-8.78%)
Market OpenUpdated 3:42 PM EDT
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fate Therapeutics, Inc. in the Healthcare sector is trading at $2.18. The stock is currently near its 52-week high of $2.47, remaining 80.2% above its 200-day moving average. Technical signals show overbought RSI of 74 and bullish MACD crossover, explaining why FATE maintains its current momentum and trend strength. The Whystock Score of 20/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 74) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.18
Potential Upside
5%
Whystock Fair Value$2.29
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Buy
Mean target$5.44+149.4%
Range$2.00 – $8.00
Fundamentals
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$159.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-65.79%
Volume
Today's trading volume
3.09M
Recent News
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of -49.53% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax (NVAX) Reports Q1 Loss, Beats Revenue Estimates
Novavax (NVAX) delivered earnings and revenue surprises of +75.68% and +100.70%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference
Fate Therapeutics (NASDAQ:FATE) used a presentation at the Needham Healthcare Conference to outline its strategy for developing “off-the-shelf” CAR T-cell therapies, highlighting clinical progress in autoimmune disease with FT819 and early proof-of-concept signals in solid tumors with FT836. Preside
Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference
Fate Therapeutics (NASDAQ:FATE) CEO Bob Valamehr outlined the company’s clinical and manufacturing strategy for FT819, an off-the-shelf allogeneic CAR T-cell therapy, during a conference fireside chat hosted by Leerink Partners senior equity research analyst Daina Graybosch. Valamehr emphasized that